The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Honoraria - Amgen; AstraZeneca; Daiichi Sankyo; Eisai; Genomic Health; Lilly; MSD Oncology; Nektar; Novartis; Pfizer; Pierre Fabre; Roche; Seagen; Tesaro; Teva
Consulting or Advisory Role - Amgen; Daiichi Sankyo; Eisai; Hexal; Lilly; Nektar; Roche
Research Funding - Novartis (Inst); Roche/Genentech (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - Daiichi Sankyo; Pfizer; Roche
 
Consulting or Advisory Role - Agendia; Amgen; Aristo; AstraZeneca; Boehringer Ingelheim; Carl Zeiss Meditec; Celgene; ClinSol; Daiichi Sankyo; Eisai; Genomic Health; GlaxoSmithKline; Hexal; Lilly; Medstrom Medical; MSD; Mundipharma; NanoString Technologies; Odonate Therapeutics; Palleos; Paxman; Pfizer; Pierre Fabre; Puma Biotechnology; RIEMSER; Roche; Sandoz/Hexal; Seagen; Tesaro; Teva
Speakers' Bureau - Agendia; Amgen; Aristo; AstraZeneca; Boehringer Ingelheim; Carl Zeiss Meditec; Celgene; ClinSol; Daiichi Sankyo; Eisai; Genomic Health; GlaxoSmithKline; Hexal; Lilly; Medstrom Medical; MSD; Mundipharma; NanoString Technologies; Odonate Therapeutics; Palleos; Paxman; Pfizer; Pierre Fabre; Puma Biotechnology; RIEMSER; Roche; Sandoz/Hexal; Seagen; Tesaro; Teva
Travel, Accommodations, Expenses - Agendia; Amgen; Aristo; AstraZeneca; Boehringer Ingelheim; Carl Zeiss Meditec; Celgene; ClinSol; Daiichi Sankyo; Eisai; Genomic Health; GlaxoSmithKline; Hexal; Lilly; Medstrom Medical; MSD; Mundipharma; NanoString Technologies; Novartis; Odonate Therapeutics; Palleos; Paxman; Pfizer; Pierre Fabre; Puma Biotechnology; RIEMSER; Roche; Sandoz/Hexal; Seagen; Tesaro; Teva
 
Consulting or Advisory Role - Amgen; AstraZeneca; Aurikamed; Biom'up; Celgene; Daiichi Sankyo; Eisai; Genomic Health; Hexal; MCI Group; Medtronic; MSD; Myriad Pharmaceuticals; NeoDynamics; Norgine; Novartis; OnkoLive; Pfizer; pfm medical; Roche; RTI Health Solutions; Tesaro; Teva
Research Funding - Genomic Health
ADAPTcycle: Adjuvant dynamic marker-adjusted personalized therapy (ADAPT) comparing endocrine therapy plus ribociclib versus chemotherapy in intermediate-risk HR+/HER2- early breast cancer (EBC).
 
Nadia Harbeck
Stock and Other Ownership Interests - West German Study Group
Honoraria - Amgen; AstraZeneca; Genomic Health; Novartis; Pfizer; Pierre Fabre; Roche; Zodiac Pharma
Consulting or Advisory Role - Agendia; AstraZeneca; Celgene; Daiichi Sankyo; Lilly; Merck Sharp & Dohme; Novartis; Odonate Therapeutics; Pfizer; Pierre Fabre; Roche/Genentech; Sandoz; Seagen; West German Study Group (I)
Research Funding - Lilly (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst)
 
Oleg Gluz
Consulting or Advisory Role - Celgene; Exact Sciences; Lilly; MSD; Novartis; Pfizer; Roche
Travel, Accommodations, Expenses - Celgene; Daiichi Sankyo; Roche
 
Matthias Christgen
No Relationships to Disclose
 
Monika Graeser
No Relationships to Disclose
 
Felix Hilpert
No Relationships to Disclose
 
Katja Krauss
Stock and Other Ownership Interests - Fresenius
Honoraria - Celgene; Roche
Research Funding - Novartis; Pfizer
Travel, Accommodations, Expenses - Medtronic
 
Marc Thill
No Relationships to Disclose
 
Mathias Warm
No Relationships to Disclose
 
Volkmar Müller
No Relationships to Disclose
 
Michael Wilhelm Braun
Honoraria - AstraZeneca; Celgene; Eisai; Genomic Health; GlaxoSmithKline; Medac; Novartis; Pfizer; Roche; RTI Health Solutions; Teva
Consulting or Advisory Role - AstraZeneca; Celgene; Eisai; Genomic Health; GlaxoSmithKline; Medac; Novartis; Pfizer; Roche; RTI Health Solutions; Teva
Travel, Accommodations, Expenses - AstraZeneca; Celgene; Eisai; Genomic Health; GlaxoSmithKline; Medac; Novartis; Pfizer; Roche; RTI Health Solutions; Teva
 
Marianne Just
No Relationships to Disclose
 
Hans Heinrich Kreipe
Honoraria - AstraZeneca; Genomic Health; Novartis; Roche Pharma AG
Travel, Accommodations, Expenses - AstraZeneca; Genomic Health; Novartis; Roche Pharma AG
 
Ulrike Nitz
Honoraria - Agendia; Amgen; Celgene; Genomic Health; NanoString Technologies; Novartis; Pfizer; Roche/Genentech; Teva
Consulting or Advisory Role - Genomic Health; Roche
Research Funding - Agendia (Inst); Amgen (Inst); Celgene (Inst); Genomic Health (Inst); Genomic Health (Inst); NanoString Technologies (Inst); Roche (Inst); Sanofi (Inst)
Expert Testimony - Genomic Health
Travel, Accommodations, Expenses - Genomic Health; Pfizer; Roche
 
Ronald E. Kates
Honoraria - Amgen (I); Celgene (I); Genomic Health (I); NanoString Technologies (I); Novartis (I); Pfizer (I); Roche (I)
Consulting or Advisory Role - Agendia (I); AstraZeneca (I); Daiichi Sankyo (I); Lilly (I); Merck Sharp & Dohme (I); Novartis (I); Odonate Therapeutics (I); Pfizer (I); Roche (I); Sandoz (I); Seagen (I)
 
Timo Schinkoethe
Leadership - CANKADO
Stock and Other Ownership Interests - CANKADO
 
Rachel Wuerstlein
No Relationships to Disclose
 
Sherko Kuemmel
Consulting or Advisory Role - Amgen; AstraZeneca; Celgene; Daiichi Sankyo; Genomic Health; Lilly; MSD Oncology; Novartis; Pfizer; pfm medical; Puma Biotechnology; Roche/Genentech; SOMATEX; Sonoscape
Travel, Accommodations, Expenses - Daiichi Sankyo; Roche; Sonoscape
(OPTIONAL) Uncompensated Relationships - West German Study Group